Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report

DOI: https://doi.org/10.2147/ccid.s468268

2024-05-30

Clinical Cosmetic and Investigational Dermatology

Abstract:Fabrizio Martora, &ast Maria Carmela Annunziata, &ast Luca Potestio, Teresa Battista, Angelo Ruggiero, Matteo Megna Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy &astThese authors contributed equally to this work Correspondence: Fabrizio Martora, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, NA, 80131, Italy, Tel +39 - 081 – 7462457, Fax +39 - 081 - 7462442, Email This case study outlines the management of a 24-year-old male with a history of juvenile nephronophthisis who underwent renal transplantation at age 12 and later required dialysis at 18 due to chronic rejection and hypertension. Subsequently, the patient developed severe Hidradenitis Suppurativa (HS) affecting the axillary, groin, and gluteal regions. Despite undergoing various systemic and intravenous antibiotic therapies, as well as Adalimumab treatment, the HS remained refractory. Adalimumab was discontinued due to a detected ejection fraction of 45% during cardiologic follow-up, likely due to COVID-19 related myocarditis. Following this, the patient was initiated on secukinumab therapy, initially undergoing an induction phase followed by maintenance dosing. Significant improvements were observed in quality of life, pain scores, and HS activity after 5 weeks of secukinumab therapy, with sustained benefits at the 6-month follow-up. Secukinumab was well tolerated, with no reported adverse events. This case underscores the effectiveness and safety of secukinumab as a therapeutic option for refractory HS, particularly in patients with comorbidities such as renal transplant recipients. Keywords: hidradenitis suppurativa, Adalimumab, antibiotic, Secukinumab Secukinumab, a monoclonal antibody of the IgG1 class, inhibits the activity of IL-17A and has demonstrated efficacy in treating plaque psoriasis and ankylosing spondylitis. As of October 31, 2023, secukinumab has also been approved for the treatment of moderate to severe forms of hidradenitis suppurativa. 1–3 Large molecules like immunoglobulins undergo minimal filtration by the kidneys. Similar biological agents are administered to patients with renal dysfunction without dose adjustment, suggesting that secukinumab can be administered at the standard dosage to such patients. However, there is currently insufficient real-world evidence regarding the safety and effectiveness of secukinumab in patients undergoing hemodialysis. In the literature, there's discussion about the affirmative impact of IL-17A inhibitors on kidney ailments. The Th17/IL-17 pathway fosters scarring, organ structure and function deterioration, resulting in podocyte harm. Hence, an IL-17A inhibitor can impede damage progression. HS is typified by persistent inflammation with potential ramifications on various bodily organs. Persistent buildup of inflammatory agents and cytokines may impede renal function, thus alleviating inflammation could prove beneficial for patients. Here we report the case of a 24-year-old boy suffering from juvenile nephronophthisis for which he performed renal transplantation at the age of 12 years; unfortunately, at age of 18 years he started dialysis treatment due to chronic rejection and concomitant hypertension. Three years later, he experienced the onset of severe HS localized to the axillary region bilaterally, groin and posterior gluteal region for which he practiced several systemic (rifampicin + clindamycin; doxycycline) and intravenous antibiotic therapies (ertapenem) with mild results. Then Adalimumab therapy for 8 months with fair results was performed; however, during the cardiologic follow-up visits that the patient regularly performed for hypertension, an ejection fraction of 45% (probably due to COVID-19 related myocarditis) was found. Hence, Adalimumab was discontinued. We decided to start secukinumab 300mg at Week 0, 1, 2, 3 and 4 (induction phase) and then 300 mg continued every 2 weeks. IHS4 at baseline was 51, DLQI 29 and severe pain (NRS, 10) (Figure 1) Figure 1 Secukinumab therapy. Before initiation of secukinumab therapy. After 5 weeks, there was an improvement in quality of life (DLQI from 29 to 8) and a reduction in pain (NRS from 10 to 3). There was also a significant reduction in HS activity (IHS4 from 51 to 19). Results have been confirmed and improved after 6 months of therapy (DLQI 4, NRS 1 and IHS4 15) (Figure 2). Secukinumab was well tolerated by the patient and no adverse events occurred. Figure 2 After 24 weeks of secukinumab therapy. Treating Hidradenitis Suppurativa (HS) has long posed a significant challenge for dermatologists. Up until recently, the first FDA-approved biologic drug for HS was adalimumab, an anti-tumor nec -Abstract Truncated-

dermatology